Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Tathmini ya Leeds ya Dalili na Ishara za Neuropathic (LANSS)× | ALS Functional Rating Scale Revised (ALSFRS-R)× | |
|---|---|---|
| Nyanja | Neurolojia | Neurolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 2001 | 1999 |
| Mwanzilishi≠ | Mark I. Bennett, University of Leeds | James M. Cedarbaum, NIH/NINDS |
| Aina≠ | Hybrid questionnaire and clinician examination | Clinician-rated and patient-reported hybrid |
| Chanzo asilia≠ | Bennett, M. I. (2001). The LANSS Pain Scale: The Leeds Assessment of Neuropathic Symptoms and Signs. Pain, 92(1-2), 147-157. DOI ↗ | Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999). The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. Journal of the Neurological Sciences, 169(1-2), 13-21. DOI ↗ |
| Majina mbadala | LANSS Pain Scale, Leeds Neuropathic Symptoms | ALS FRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised |
| Zinazohusiana | 4 | 4 |
| Muhtasari≠ | The LANSS is a brief seven-item hybrid screening and diagnostic tool designed to differentiate neuropathic pain from non-neuropathic (nociceptive) pain. Developed by Mark Bennett at the University of Leeds in 2001, it combines five patient-reported symptom items with two clinician-performed neurological examination findings. With a sensitivity of 82% and specificity of 80%, LANSS is among the most accurate tools for identifying whether a patient's pain has a neuropathic component, making it invaluable in clinical practice and research settings where pain etiology classification is essential. | The ALSFRS-R is a 12-item clinician-administered functional rating scale designed to assess disease progression and functional status in amyotrophic lateral sclerosis (ALS). Introduced by Cedarbaum and colleagues in 1999, it expands upon the original ALSFRS by incorporating respiratory function assessment. It is the primary outcome measure in ALS clinical trials and routine clinical monitoring, providing quantitative tracking of disease decline that predicts survival and guides management decisions. |
| ScholarGateSeti ya data ↗ |
|
|